All Specialties
Login
/
Register
SIGN UP
NEWS
CONDITION CENTERS
CONFERENCE COVERAGE
PEER EXCHANGE
MEDIA
Peers and Perspectives
Insights
News Network
Podcasts
Post-Conference Perspectives
Spotlights
Live Broadcast
Cardiology
Dermatology
Endocrinology
Family Medicine
Gastroenterology
Geriatrics
Hospital Medicine
Infectious Disease
Internal Medicine
Neurology
Ophthalmology
Pain Management
Pediatrics
Psychiatry
Pulmonology
Rare Disease Report
®
Rheumatology
Surgery
All Specialties
Cardiology
Dermatology
Endocrinology
Family Medicine
Gastroenterology
Geriatrics
Hospital Medicine
Infectious Disease
Internal Medicine
Neurology
Ophthalmology
Pain Management
Pediatrics
Psychiatry
Pulmonology
Rare Disease Report
®
Rheumatology
Surgery
test
View All Conferences
AASLD 2018 | The Liver Meeting
AASLD 2018 (aka The Liver Meeting) features groundbreaking basic, translational, and clinical research in diseases of the liver and biliary tract, and in liver transplantation.
Hepatitis C Reinfection Rates Greater in Drug Users Despite DAAs
Investigators also found that opiate agonist therapy could have a positive effect in limiting reinfection rates after patients achieve SVR.
High-Risk Opioid Prescriptions Associated with Hepatic Decompensation
For patients with chronic liver disease, opioid prescriptions are common, and high-risk prescriptions are associated with hepatic decompensation, especially ascites.
Hospitalizations Due to Alcoholic Liver Disease Have Risen 12%
ALD-related hospitalizations grew from 2008 to 2014, especially among women, Asians, Hispanics, and people 50 to 69 years of age.
Severe Hepatic Steatosis and Thrombocytopenia Increase Risk of All-Cause, Cardiovascular-Related Mortality
No studies to-date have looked at the combined risk of mortality for patients with thrombocytopenia and severe hepatic steatosis.
Non-Alcoholic Fatty Liver Disease Explains Chronic-Liver-Disease-Related Mortality
The leading etiologies for chronic-liver-disease-related-deaths over the last decade can be explained by NAFLD and alcoholic liver disease.
Hepatitis C Present in Nasal, Rectal Fluids in High Viral Load Patients
A new study confirms that HCV-RNA can be found in the nasal and rectal fluids of patients with high viral loads of HCV, raising the possibility of HCV transmission via these fluids.
Renally-Impaired Patients with Chronic Hepatitis B Virus Infection Find Success with Low Dose of TDF
A low dose of TDF may help to preserve renal function and maintain viral suppression in patients with chronic hepatitis B virus infection, even those with advanced liver disease.
Norah Terrault, MD, MPH: Benefits of Avatrombopag for Thrombocytopenia
After the therapy was approved by the FDA in May, investigators are anticipating its first real-world data will paint a clearer picture of its potential.
Obesity Associated with Greater Morbidity in Cirrhotic Patients with Variceal Bleeding
Cirrhotic patients with variceal bleeding were found to have greater morbidity in association with obesity.
Donna Cryer: Biggest Liver Meeting Takeaways
How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.
Terlipressin Improves Survival Rates of Lower-MAP Patients with HRS-1
HRS-1 is a rare, acute complication of liver cirrhosis characterized by life-threatening and rapid progression that can end in renal failure. Terlipressin, a vasopressin analogue, could become the first therapy approved for the treatment of HRS-1 in the US.
Norah Terrault, MPH, MD: Cannabis Use Affects Liver Transplant Status
Norah Terrault, MPH, MD, explains how the use of cannabis can affect a patient's status on the liver transplant list.
Norah Terrault, MPH, MD: Managing DAA Failures When Treating Hepatitis C Virus Infections
Norah Terrault, MPH, MD, discusses gaps in treatment in people who are infected with hepatitis C virus and what steps clinicians should take when treating these patients.
Proof of Concept Study Indicates Hepatitis C Virus Treatment Could Be Cut in Half for Some Patients
The new approach could shave off time and costs from the current standard regimen.
Glecaprevir/Pibrentasvir Demonstrates SVR in Treatment-Naive Patients with Hepatitis C Virus and Compensated Cirrhosis
At 12 weeks post treatment per protocol analysis with 8 weeks of glecaprevir/pibrentasvir treatment, patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response.
Norah Terrault, MPH, MD: Cannabis Use in Liver Disease
Norah Terrault, MPH, MD, addresses the many unanswered questions and data surrounding cannabis use in liver disease.
Vosevi, Mavyret Report Strong HCV Efficacy in Real-World Setting
Investigators praised the excellent effectiveness of both therapies, but advised care regarding the increased odds of adverse events requiring hospitalizations.
Clostridium Difficile
Infection Associated With Higher Mortality Rates in Patients With Cirrhosis
Clostridium difficile
infection leads to higher rates of overall mortality among patients with cirrhosis compared to those who do not have the condition.
Mood-Altering Medications Do Not Increase Risk for Post-TIPS Hepatic Encephalopathy
The use of mood-altering medications does not increase odds for hepatic encephalopathy or hepatic encephalopathy-related hospital admissions after TIPS placement, according to the results of a new study.
PWID Infected With Hepatitis C Virus Can Achieve SVR Despite Imperfect Adherence to Treatment
People who inject drugs who are infected with hepatitis C virus can achieve sustained viral response at the completion of treatment, despite imperfect adherence.
Nonalcoholic Fatty Liver Disease May Be Underappreciated Comorbidity Among People With HIV
Research on nonalcoholic fatty liver disease in persons infected with HIV revealed a prevalence of the condition of about 40%.
Additional Risk Factors for Acute Kidney Injury Defined in Patients with Cirrhosis
Although acute kidney injury is common in patients with cirrhosis, those who are admitted to the hospital are at increased risk, especially if they are of older age, Child-Pugh Class C, or have ascites or sepsis.
Higher Dose of Simvastatin Leads to Increased Toxicity for Patients With Decompensated Cirrhosis
Data from a phase 2, double-blind, placebo-controlled study, showed a higher dose of simvastatin was associated with greater liver and muscle toxicity compared with a lower dose for patients with decompensated cirrhosis.
SOF/VEL/VOX Successful for Hepatitis C Virus Retreatment in Patients With and Without HIV
Treatment was also successful in patients with prior noncompletion or poor adherence to direct-acting antiviral therapy.
Risk of Metabolic Complications Post Liver Transplant Reduced with Pre-Transplant Weight Loss Surgery
Obese patients who underwent weight-loss surgery prior to receiving a liver transplant had a significantly lower risk of metabolic complications post-transplant than those who followed medical weight loss prior to transplant.
ARO-HBV Reduces All Measurable Viral Products in Patients with Chronic Hepatitis B Virus Infection
The first results of a study on the use of monthly RNAi with ARO-HBV in patients with chronic hepatitis B virus infections indicate that the treatment effectively reduced all measurable viral products, including HBsAg.
Platelet Count Influences Thrombopoietin Metabolism
The biology of thrombopoietin metabolism in advanced liver disease may be influenced by platelet count and degree of liver failure.
Most Popular
Humberto Choi, MD: Screening & Treatment Overlap in Lung Cancer, COPD
Robert Wise, MD: Exacerbation Reduction with Aclidinium Bromide
Guidelines for Exercise After a Tummy Tuck Procedure
DocTalk Podcast: 2019 in Review with Deepak Bhatt, MD, MPH
FDA Approves Babesia Blood Test System
